Synergistic interactions of TRAIL and paclitaxel on the laryngeal squamous carcinoma cell line in vitro.
- Author:
Ming ZHANG
1
;
Liang ZHOU
;
Ming XIE
;
Jie TIAN
Author Information
1. Department of Otolaryngology, Eye Ear Nose Throat Hospital, Fudan University, Shanghai, 200031, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
drug effects;
Carcinoma, Squamous Cell;
drug therapy;
Cell Line, Tumor;
Drug Synergism;
Humans;
Laryngeal Neoplasms;
drug therapy;
Paclitaxel;
pharmacology;
TNF-Related Apoptosis-Inducing Ligand;
pharmacology
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2007;21(24):1105-1108
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the synergistic cytotoxicity of TRAIL and paclitaxel on laryngeal squamous carcinoma cell line Hep-2.
METHOD:Hep-2 cells were exposed to various concentrations of TRAIL and paclitaxel respectively or jointly. The inhibition rate was measured by CCK-8 assay. The apoptosis rate and the expressions of DR4, DR5, DcR1 and DcR2 in Hep-2 cells were detected by flow cytometry methods.
RESULT:Hep-2 cells were resistant to apoptosis induced by TRAIL. Paclitaxel could enhance its sensitivity to TRAIL by up-regulating the expressions of TRAIL death receptors in Hep-2 cells.
CONCLUSION:The resistance of Hep-2 cell to TRAIL could be overcome by paclitaxel. TRAIL and paclitaxel have synergistic killing effects on Hep-2 cells, so they might have a promising prospect in clinical therapy of laryngeal squamous carcinoma.
